Top News

  • Trustees approve construction of Regional Academic Health Center, health sciences building

    During its Dec. 1 meeting, the Indiana University Board of Trustees formally approved construction of the Regional Academic Health Center/Academic Health Sciences Building in Bloomington. A joint project with Indiana University Health, the Regional Academic Health Center/Academic Health Sciences Building will provide a replacement hospital for the current IU Health Bloomington facility and an Academic Health Sciences Building for use by IU.  

    About 65 acres of land near the IU Golf Course will be leased to IU Health. About half of the acreage will be used for this development project, and the other half will be held for future growth. The academic space will include faculty offices, classrooms and related spaces for programs in nursing, medical science, speech and hearing sciences, and social work.

    “The Regional Academic Health Center/Academic Health Sciences Building is a win-win-win opportunity," said Thomas Morrison, IU vice president for capital planning and facilities. "This complex will benefit Indiana University, IU Health and, most importantly, our local community.” 

    For more details on this project and other university construction approved by the board last week, read this special edition of Inside IU.

    Back to Top ▲

  • Plan ahead for last 2016 issue of InScope

    The Dec. 15 InScope will be the last issue published before the holiday break. Distribution will resume on Thursday, Jan. 5, 2017. Editorial planning is underway for next week’s issue, which will include an IU School of Medicine “year in review” feature.

    Submit news items for the Dec. 15 issue by Tuesday, Dec. 13, to

    Back to Top ▲

Research News

  • Vidal receives $450K Alzheimer?s Association Zenith Fellows Award

    Ruben Vidal, PhD, professor of pathology and laboratory medicine, has been named one of four recipients nationally of the prestigious 2017 Zenith Fellows Award from the Alzheimer’s Association. Extremely competitive, the Zenith Awards program provides support for investigators who have contributed significantly to the field of Alzheimer’s disease research and are likely to make substantial contributions in the future.

    The $450,000 award, provided over three years, will allow Dr. Vidal's lab to pursue research looking at pathways that are critical in the Alzheimer's disease process, particularly to understand how tau protein may drive the disease progression with the aim of developing therapies and prevent the progression of the disease.

    For years, investigators have focused on the study of ß-amyloid protein, however, recent research work has highlighted the role of a protein called tau in Alzheimer’s disease.

    “Tau deposits—not amyloid—are closely linked to symptoms such as memory loss and dementia,” Dr. Vidal said. “In broad terms, my Zenith Award research will focus on the cell types that are involved in tau propagation in vivo so that we can gain new knowledge of the pathways involved in the progression of the disease and predict the potential usefulness of target therapies. This award is only given to a handful of individuals each year, so I feel extremely honored to receive it.”

    Back to Top ▲

  • November research awards total nearly $3.6 million

    Investigator Sponsor Type Project Title Begin Date End Date Awarded Dollars
    Cynthia Diane Brown Dartmouth College New CF Virtual Improvement Program - Fundamentals 2 (VIP-F2) - Grant Award 7/1/2016 6/30/2017 1,350
    Peng-Sheng Chen Northwestern University New Stellate Ganglion Blockade for the Management of Vasomotor Symptoms 8/1/2016 4/30/2017 15,118
    Matthias A. Clauss Virginia Commonwealth University New Central Role of Endothelial Stem Cells in Pulmonary Arterial Hypertension 8/1/2016 7/31/2017 9,606
    Eric S. Ebenroth Riley Children's Foundation New D-Transposition of the Great Arteries 7/1/2016 6/30/2017 79,000
    Tatiana M. Foroud Michael J Fox Foundation For Parkinsons Research New Observational Study Planning - Fox BioNet (FBN) 9/1/2016 12/31/2016 10,000
    Tatiana M. Foroud Alzheimer Association New Amyloid Neuroimaging and Genetics Initiative (ANGI) 10/1/2016 9/30/2017 449,400
    Takashi Hato Dialysis Clinic, Inc. New Mechanisms of direct renal injury in sepsis. 2/1/2017 1/31/2018 60,000
    Chandy C. John Doris Duke Charitable Foundation New Optimizing hydroxyurea therapy in children with sickle cell anemia in malaria endemic areas 9/15/2016 9/14/2017 48,604
    Katherine J. Kelly University Of Alabama Birmingham New Hepatorenal Fibrocystic Disease 7/1/2016 6/30/2017 62,400
    Katherine J. Kelly Dialysis Clinic, Inc. Renewal (not prev committed) Novel Means of Gene delivery in Polycystic Kidney Disease. 2/1/2017 1/31/2018 60,000
    Bruce Timothy Lamb U.S. Department Of Defense New The Role of Inflammation in Development of AD Following Repetitive Head Trauma 8/1/2015 10/31/2018 635,176
    Ulrike Mietzsch Regents Of The University Of California New High-dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) CCC 9/30/2016 6/30/2017 18,725
    Jean P. Molleston Arbor Research Collaborative For Health New FibroScan in Pediatric Cholestatic Liver Disease (FORCE) 9/20/2016 5/31/2017 34,600
    Kenneth P. Nephew Massachusetts General Hospital New The Genomic, Epigenomic and Quality of Life Characteristics of Long-Term Survivors of Ovarian Cancer 9/30/2016 9/29/2017 99,832
    David B. Pisoni National Institute on Deafness and Other Communication Disorders New Executive Functioning and Speech-Language Skills in Cochlear Implant Users 12/1/2016 11/30/2017 633,958
    Jamie L. Renbarger National Institute of Child Health and Human Development New Indiana University Center for Pediatric Pharmacology and Precision Medicine 9/22/2016 6/30/2017 823,069
    Peter J. Roach University Of Kentucky New Lafora Epilepsy- Basic Mechanisms to Therapy (Admin Core) 7/1/2016 6/30/2017 281,630
    Andrew J. Saykin Georgetown University New Bio-behavioral Research at the Intersection of Cancer and Aging 8/1/2016 11/30/2017 222,539
    Dimitrios Stefanidis Society Of American Gastrointestinal & Endoscopic Surgeons New Development and Statewide Implementation of a Fundamentals of Endoscopic Surgery Proficiency-Based Curriculum for General Surgery Residents 10/3/2016 6/30/2017 10,418

    Back to Top ▲

  • Grants will boost research into family of fatal genetic diseases

    Researchers at Indiana University School of Medicine have received $4.4 million to identify new treatments for a family of fatal genetic diseases.

    Peter J. Roach, PhD, distinguished professor of biochemistry and molecular biology, and the IU School of Medicine team believes that their research could lead to a new therapeutic paradigm to combat glycogen storage diseases by identifying drugs that can suppress glycogen accumulation. Their work will be supported by two five-year grants from the National Institutes of Health.

    Glycogen is a normal storage form of glucose found in many tissues like muscle, heart, liver and brain. In the glycogen storage diseases, including Lafora and Pompe diseases, some of the glycogen becomes abnormal due to defects in glycogen metabolism, and can cause fatal illnesses.

    In Lafora disease, the first symptom seen in apparently healthy youngsters is a major epileptic episode in their early to mid-teens. This is followed by a gradual neurological deterioration and death within ten years. The cause of Lafora disease is thought to be abnormal glycogen deposits in the neurons of the brain. Currently, there is no cure or specific therapy for this fatal disease.

    In Pompe disease, there is abnormal glycogen accumulation in the skeletal muscle and the heart. The severity of the disease varies with the genetic makeup of the patient. However, in the most serious cases, the patients die before their first birthday. Existing treatments include enzyme replacement therapy, but there is a clear need for improved approaches, according to the IU School of Medicine researchers.

    The IU School of Medicine team has found that by decreasing glycogen accumulation in genetically modified mice, the symptoms of Lafora and Pompe diseases can be alleviated. With this premise, Dr. Roach and his colleagues, have focused their research on discovering small molecule drugs that can decrease glycogen accumulation.

    Read more in the IU School of Medicine Newsroom.

    Back to Top ▲

Faculty and Staff News

  • Holiday PTO and year-end pay

    As 2016 draws to a close, IU Human Resources sent a notification to employees about final paychecks for the year, and how and when to use time off during the holidays.

    Year-end pay dates 

    For support, service, and PAO and PAU professional staff, the last pay date of 2016 is Dec. 30, 2016, for time worked between Dec. 4 and 17, 2016. PAE professional staff will receive pay for work during December on Jan. 3, 2017.

    Use of 2016 holiday hours

    Unused holiday accruals from 2015 must be used by the end of the last pay period of 2016. For support, service, and PAO and PAU staff, holiday time off earned in 2015 must be used by Dec. 31, 2016. For PAE staff, holiday time off earned in 2015 must be used by Dec. 31, 2016.

    Use of paid time off during departmental closings

    Paid holidays for Christmas Day and New Year’s Day will be Monday, Dec. 26, 2016, and Monday, Jan. 2, 2017, respectively. To receive pay for the time a department is closed between these dates, support and service staff must use accrued vacation hours or accrued compensatory time off; PAO and PAU staff must use PTO or accrued compensatory time off; and PAE staff must use accrued PTO.

    For more details and information about borrowing future vacation or PTO accruals, visit

    Back to Top ▲


  • Jan. 10 is deadline to apply for IU School of Medicine internal grants

    A month remains to apply for the IU School of Medicine Biomedical Research Grant and the Research Enhancement Grant. Applications are due by 5 pm, Tuesday, Jan. 10.

    Investigators desiring administrative review of the application components to ensure compliance with posted submission guidelines must submit the proposal to at least five business days before the Jan. 10 deadline. If an application is not received five business days prior to the deadline, it is assumed the principal investigator has waived administrative review rights. In this case, the proposal should be uploaded directly to the CTSI website and may be subject to administrative withdrawal if not compliant with guidelines. 

    For application forms and further information, visit

    Back to Top ▲

  • Indiana CTSI postdoctoral training award applications due Jan. 13

    The Indiana Clinical and Translational Sciences Institute (CTSI) postdoctoral training awards in translational research provide promising postdoctoral fellows the opportunity to be mentored in research-intensive, multi-disciplinary settings to prepare for careers in translational research.

    Translational research is commonly referred to as "bench to bedside," the process by which research in the lab translates into patient treatment. Translational research may involve applying discoveries made during work in a lab, developing clinical trials and studies in humans or carrying out research aimed at enhancing best practices.

    Candidates for these awards must be from IUPUI, Indiana University-Bloomington, Purdue University-West Lafayette or University of Notre Dame and be a U.S. citizen or have permanent resident status. Additional eligibility requirements and information about the application process are available at Application deadline is 5 pm, Friday, Jan. 13.

    Back to Top ▲

  • Apply for Indiana CTSI young investigator awards by Jan. 17

    Junior investigator faculty interested in further developing their careers in clinical-translational research are encouraged to apply for the Indiana Clinical and Translational Sciences Institute (CTSI) young investigator awards. Awards include the opportunity to be mentored in research-intensive multi-disciplinary settings. Clinical research includes epidemiological studies, clinical trials or other investigations involving human subjects. Translational research consists of either “T1 research” (interface of basic science to human studies) or “T2 research” (interface of human studies to the community).

    Benefits include partial salary support, as well as tuition and fees for required and elective coursework, pilot research monies and travel funds to attend the national CTSI young investigator meeting. Eligibility requirements and application details are available at Application deadline is Tuesday, Jan. 17, and awards will begin July 1, 2017.  With general questions, contact Donna Burgett at

    Back to Top ▲

Partner News

  • Enterprise Alignment update

    IU Health Physicians and Indiana University School of Medicine recently announced new developments related to Enterprise Alignment -- the organizations’ commitment to promote better care across the Indianapolis metropolitan region.

    Planning efforts for the funds flow project, a major joint initiative between IU School of Medicine and IU Health, is well underway. To focus on implementing a model that can be reproduced periodically throughout the 2017 funds flow shadow year, the organizations have shifted resources to focus on driving this initiative forward internally to Ashley Ray, associate director, IU School of Medicine Dean’s Office -- Financial Services, and Bonnie Hoy, funds flow manager, IU Health, who will be leading this project going forward.

    Additionally, two recent appointments have been announced. Kim Ammon has been named vice chair, clinical and academic administration, Department of Orthopaedics, effective immediately. Since 2011, Ammon has served as service line administrator for IU Health Physicians Orthopaedics, where she oversaw operations for seven sites and more than 100 team members. Working closely with Daniel Wurtz, MD, chair of orthopaedic surgery, Ammon will expand her current role to support the academic and research mission within orthopaedic surgery.

    Chris Kellams has been named vice chair, clinical and academic administration, Department of Psychiatry, effective immediately. Since February, Kellams has served as service line administrator for the IU Health Physicians Kidney Diseases, Kidney Transplant and Infectious Diseases service lines. In his current role, he has led efforts to operationally integrate the two infectious diseases physician groups into one service line with the help of the administrative team. Working closely with Thomas McAllister, MD, chair of psychiatry, Kellams will oversee the financial and administrative functions of the department, encompassing the missions of education, research, and clinical operations.

    Back to Top ▲